Tadashi Nomizu - Profile on Academia.edu (original) (raw)
Papers by Tadashi Nomizu
[Genetic diagnosis of familial breast cancer]
Nippon Rinsho Japanese Journal of Clinical Medicine, Sep 1, 2012
Preventive and/or therapeutic agent of hand-foot syndrome
The Japanese Journal of Surgery, Jun 1, 1990
Three cases of squamous cell carcinoma of the thyroid are reported herein. In all cases, the carc... more Three cases of squamous cell carcinoma of the thyroid are reported herein. In all cases, the carcinoma occurred in old age and was characterized by a rapidly growing tumor, usually associated with dyspnea and dysphagia. The prognosis of all 3 cases was poor, with a mean survival of only 6.3 months. Although squamous metaplasia is an accepted etiology of this disease, clinical investigation of the cases presented here does not favor it in consideration of the clinical features of papillary carcinoma of the thyroid with squamous metaplasia. The histological findings of our cases revealed areas of cystic formation, suggesting that some of these carcinomas may be derived from remnants of embryonic origin.
若年者早期空腸癌の1例
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2012
Annals of Oncology, Oct 1, 2014
We have reported that status of the TP53 mutation is predictable by expression profile of 33 gene... more We have reported that status of the TP53 mutation is predictable by expression profile of 33 genes (TP53 signature) in breast cancer and that the TP53 signature can predict overall survival and recurrent free survival of early breast cancer (Cancer Sci. 99: 324-32, 2008). The aim of this study is to determine whether the TP53 signature can also predict both the efficacy of NAC and the recurrence after surgery in breast cancer. Methods: An NAC cohort (E-GEOD-25066) that contains 508 patients with HER2 negative breast cancer is used. Among the genes previously used TP53 signature, 20 up-regulated and 5 down-regulated genes in breast cancer with TP53 mutation were selected and the TP53 status was determined by the ratio of the sum of expression values of 20 up-regulated genes to that of the 5 down-regulated genes. If the ratio (down / up) was less than 0.325, the tumor was determined as aTP53 mutant. If it was greater than or equal to 0.325, the tumor was determined aTP53 wild. Results: Fifty percent (255 of 508) of tumors was determined as a TP53 mutant. The pathological CR ( pCR) rate is significantly higher in TP53 mutant tumor than in TP53 wild-type tumor (34.7% vs 5.4%). In Stage I and II patients (n = 280), recurrence free survival (RFS) was significantly better in patients with TP53 wild type tumor (P = 0.0018). Patients with TP53 mutant tumor not leading to pCR (mt / non-pCR) showed significantly worse RFS than the other patients (P < 0.001). In ER positive and triple negative subgroup, RFS were also worse in patients with mt / non-pCR. Conclusions: TP53 signature has the ability to predict the efficacy of NAC and recurrence after surgery in breast cancer. The TP53 signature was especially useful to predict the recurrence in combination with pCR status. Our data suggests that patients with TP53 mutant tumor not leading to pCR after NAC may need adjuvant chemotherapy after surgery to improve prognosis of these patients.
Second Primary Breast Cancer Following Thyroid Cancer: Report of Two Cases
Japanese Journal of Clinical Oncology, Dec 1, 1983
Two cases of second primary breast cancer following thyroid cancer are presented. The association... more Two cases of second primary breast cancer following thyroid cancer are presented. The association between breast and thyroid cancer is reviewed from the literature, but no common etiologic factor is found between the two neoplasms in our experience.
Breast Cancer, Apr 1, 1999
A case of breast cancer that metastasized to the head of the pancreas 6 years and 8 months after ... more A case of breast cancer that metastasized to the head of the pancreas 6 years and 8 months after mastectomy is reported. The pancreas head metastasis was associated with general fatigue and obstructive jaundice. The serum levels of CEA, CA15-3 and NCC-ST-439, tumor markers of breast cancer, were within normal limits, but CA15-3 was immunohistochemically demonstrated in the resected metastatic lesion, in a manner similar to Iobular carcinoma of the breast.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]
Gan to Kagaku Ryoho Cancer Chemotherapy, Jun 1, 2002
In the first part of this late phase II study, we determined the recommended clinical dose of CGS... more In the first part of this late phase II study, we determined the recommended clinical dose of CGS20267 to be 1.0 mg once daily for the treatment of postmenopausal women with advanced or recurrent breast cancer. To further evaluate the efficacy and safety of CGS20267 at the derived or recommended clinical dose, 30 more patients were enrolled in the second part of the study, and were added to the patients treated at 1.0 mg in the first part. As a result of putting the first and second parts together, the objective response rate at 1.0 mg was found to be 38.3%, which was almost equal to that of the early phase II study (40.7%). Drug-related adverse events occurred in 35.4% of the patients at 1.0 mg, and all of the events were of grade 2 or lower. These results demonstrated that CGS20267 1.0 mg once daily is effective and well tolerated in the treatment of postmenopausal women with advanced or recurrent breast cancer.
A Case of Mammary Carcinoma Associated with Acromegary
The journal of the Japanese Practical Surgeon Society, 1989
The Japanese Journal of Surgery, 1988
A case of apocrine carcinoma of the breast is reported herein. Apocrine carcinoma is a rare tumor... more A case of apocrine carcinoma of the breast is reported herein. Apocrine carcinoma is a rare tumor characteristically composed of large cells with eosinophilic cytoplasm. This case involves a 34-year old woman who underwent a modified radical mastectomy and is now doing well with no evidence of recurrence, 10 months after her surgery, KEY WORDS: breast carcinoma, apocrine carcinoma
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]
Gan to kagaku ryoho. Cancer & chemotherapy
In the first part of this late phase II study, we determined the recommended clinical dose of CGS... more In the first part of this late phase II study, we determined the recommended clinical dose of CGS20267 to be 1.0 mg once daily for the treatment of postmenopausal women with advanced or recurrent breast cancer. To further evaluate the efficacy and safety of CGS20267 at the derived or recommended clinical dose, 30 more patients were enrolled in the second part of the study, and were added to the patients treated at 1.0 mg in the first part. As a result of putting the first and second parts together, the objective response rate at 1.0 mg was found to be 38.3%, which was almost equal to that of the early phase II study (40.7%). Drug-related adverse events occurred in 35.4% of the patients at 1.0 mg, and all of the events were of grade 2 or lower. These results demonstrated that CGS20267 1.0 mg once daily is effective and well tolerated in the treatment of postmenopausal women with advanced or recurrent breast cancer.
A Case of Gastritis Cystica Polyposa
The journal of the Japanese Practical Surgeon Society, 1988
A Case of Amebic Absces of the Liver with Difficulties in Diagnosing and Treating
The journal of the Japanese Practical Surgeon Society, 1992
消化器癌の家族内集積症例について
The Japanese Journal of Gastroenterological Surgery, 1986
遺伝性非ポリポーシス大腸癌の手術術式の適応と遺伝子診断
The Japanese Journal of Gastroenterological Surgery, 1997
A Case of Familial Polyposis Coli with Familial Clustering of Gastric Cancer
The journal of the Japanese Practical Surgeon Society, 1989
The Primary Smooth Muscle Tumor of the Stomach
The journal of the Japanese Practical Surgeon Society, 1989
The Clinical Significance of Serum SLX Level in Patients with Malignant Tumor
The journal of the Japanese Practical Surgeon Society, 1989
ABSTRACT
Two Cases of Brain Metastasis of Colorectal Cancer
The journal of the Japanese Practical Surgeon Society, 1986
Adenosquamous Cell Carcinoma of the Bile Duct with an Early Gastric Cancer-A Case Report
The journal of the Japanese Practical Surgeon Society, 1994
[Genetic diagnosis of familial breast cancer]
Nippon Rinsho Japanese Journal of Clinical Medicine, Sep 1, 2012
Preventive and/or therapeutic agent of hand-foot syndrome
The Japanese Journal of Surgery, Jun 1, 1990
Three cases of squamous cell carcinoma of the thyroid are reported herein. In all cases, the carc... more Three cases of squamous cell carcinoma of the thyroid are reported herein. In all cases, the carcinoma occurred in old age and was characterized by a rapidly growing tumor, usually associated with dyspnea and dysphagia. The prognosis of all 3 cases was poor, with a mean survival of only 6.3 months. Although squamous metaplasia is an accepted etiology of this disease, clinical investigation of the cases presented here does not favor it in consideration of the clinical features of papillary carcinoma of the thyroid with squamous metaplasia. The histological findings of our cases revealed areas of cystic formation, suggesting that some of these carcinomas may be derived from remnants of embryonic origin.
若年者早期空腸癌の1例
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2012
Annals of Oncology, Oct 1, 2014
We have reported that status of the TP53 mutation is predictable by expression profile of 33 gene... more We have reported that status of the TP53 mutation is predictable by expression profile of 33 genes (TP53 signature) in breast cancer and that the TP53 signature can predict overall survival and recurrent free survival of early breast cancer (Cancer Sci. 99: 324-32, 2008). The aim of this study is to determine whether the TP53 signature can also predict both the efficacy of NAC and the recurrence after surgery in breast cancer. Methods: An NAC cohort (E-GEOD-25066) that contains 508 patients with HER2 negative breast cancer is used. Among the genes previously used TP53 signature, 20 up-regulated and 5 down-regulated genes in breast cancer with TP53 mutation were selected and the TP53 status was determined by the ratio of the sum of expression values of 20 up-regulated genes to that of the 5 down-regulated genes. If the ratio (down / up) was less than 0.325, the tumor was determined as aTP53 mutant. If it was greater than or equal to 0.325, the tumor was determined aTP53 wild. Results: Fifty percent (255 of 508) of tumors was determined as a TP53 mutant. The pathological CR ( pCR) rate is significantly higher in TP53 mutant tumor than in TP53 wild-type tumor (34.7% vs 5.4%). In Stage I and II patients (n = 280), recurrence free survival (RFS) was significantly better in patients with TP53 wild type tumor (P = 0.0018). Patients with TP53 mutant tumor not leading to pCR (mt / non-pCR) showed significantly worse RFS than the other patients (P < 0.001). In ER positive and triple negative subgroup, RFS were also worse in patients with mt / non-pCR. Conclusions: TP53 signature has the ability to predict the efficacy of NAC and recurrence after surgery in breast cancer. The TP53 signature was especially useful to predict the recurrence in combination with pCR status. Our data suggests that patients with TP53 mutant tumor not leading to pCR after NAC may need adjuvant chemotherapy after surgery to improve prognosis of these patients.
Second Primary Breast Cancer Following Thyroid Cancer: Report of Two Cases
Japanese Journal of Clinical Oncology, Dec 1, 1983
Two cases of second primary breast cancer following thyroid cancer are presented. The association... more Two cases of second primary breast cancer following thyroid cancer are presented. The association between breast and thyroid cancer is reviewed from the literature, but no common etiologic factor is found between the two neoplasms in our experience.
Breast Cancer, Apr 1, 1999
A case of breast cancer that metastasized to the head of the pancreas 6 years and 8 months after ... more A case of breast cancer that metastasized to the head of the pancreas 6 years and 8 months after mastectomy is reported. The pancreas head metastasis was associated with general fatigue and obstructive jaundice. The serum levels of CEA, CA15-3 and NCC-ST-439, tumor markers of breast cancer, were within normal limits, but CA15-3 was immunohistochemically demonstrated in the resected metastatic lesion, in a manner similar to Iobular carcinoma of the breast.
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]
Gan to Kagaku Ryoho Cancer Chemotherapy, Jun 1, 2002
In the first part of this late phase II study, we determined the recommended clinical dose of CGS... more In the first part of this late phase II study, we determined the recommended clinical dose of CGS20267 to be 1.0 mg once daily for the treatment of postmenopausal women with advanced or recurrent breast cancer. To further evaluate the efficacy and safety of CGS20267 at the derived or recommended clinical dose, 30 more patients were enrolled in the second part of the study, and were added to the patients treated at 1.0 mg in the first part. As a result of putting the first and second parts together, the objective response rate at 1.0 mg was found to be 38.3%, which was almost equal to that of the early phase II study (40.7%). Drug-related adverse events occurred in 35.4% of the patients at 1.0 mg, and all of the events were of grade 2 or lower. These results demonstrated that CGS20267 1.0 mg once daily is effective and well tolerated in the treatment of postmenopausal women with advanced or recurrent breast cancer.
A Case of Mammary Carcinoma Associated with Acromegary
The journal of the Japanese Practical Surgeon Society, 1989
The Japanese Journal of Surgery, 1988
A case of apocrine carcinoma of the breast is reported herein. Apocrine carcinoma is a rare tumor... more A case of apocrine carcinoma of the breast is reported herein. Apocrine carcinoma is a rare tumor characteristically composed of large cells with eosinophilic cytoplasm. This case involves a 34-year old woman who underwent a modified radical mastectomy and is now doing well with no evidence of recurrence, 10 months after her surgery, KEY WORDS: breast carcinoma, apocrine carcinoma
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]
Gan to kagaku ryoho. Cancer & chemotherapy
In the first part of this late phase II study, we determined the recommended clinical dose of CGS... more In the first part of this late phase II study, we determined the recommended clinical dose of CGS20267 to be 1.0 mg once daily for the treatment of postmenopausal women with advanced or recurrent breast cancer. To further evaluate the efficacy and safety of CGS20267 at the derived or recommended clinical dose, 30 more patients were enrolled in the second part of the study, and were added to the patients treated at 1.0 mg in the first part. As a result of putting the first and second parts together, the objective response rate at 1.0 mg was found to be 38.3%, which was almost equal to that of the early phase II study (40.7%). Drug-related adverse events occurred in 35.4% of the patients at 1.0 mg, and all of the events were of grade 2 or lower. These results demonstrated that CGS20267 1.0 mg once daily is effective and well tolerated in the treatment of postmenopausal women with advanced or recurrent breast cancer.
A Case of Gastritis Cystica Polyposa
The journal of the Japanese Practical Surgeon Society, 1988
A Case of Amebic Absces of the Liver with Difficulties in Diagnosing and Treating
The journal of the Japanese Practical Surgeon Society, 1992
消化器癌の家族内集積症例について
The Japanese Journal of Gastroenterological Surgery, 1986
遺伝性非ポリポーシス大腸癌の手術術式の適応と遺伝子診断
The Japanese Journal of Gastroenterological Surgery, 1997
A Case of Familial Polyposis Coli with Familial Clustering of Gastric Cancer
The journal of the Japanese Practical Surgeon Society, 1989
The Primary Smooth Muscle Tumor of the Stomach
The journal of the Japanese Practical Surgeon Society, 1989
The Clinical Significance of Serum SLX Level in Patients with Malignant Tumor
The journal of the Japanese Practical Surgeon Society, 1989
ABSTRACT
Two Cases of Brain Metastasis of Colorectal Cancer
The journal of the Japanese Practical Surgeon Society, 1986
Adenosquamous Cell Carcinoma of the Bile Duct with an Early Gastric Cancer-A Case Report
The journal of the Japanese Practical Surgeon Society, 1994